



# A patient-friendly approach to improved cancer care

Programme Presentation 2026



# Disclaimer

THIS PRESENTATION AND ANY OTHER INFORMATION DISCUSSED AT THE PRESENTATION (THE "PRESENTATION") IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION, WHICH HAS BEEN PREPARED AND IS ISSUED BY VASODYNAMICS LIMITED (THE "ISSUER"), IS PRELIMINARY IN NATURE, BASED ON MANAGEMENT BELIEFS AND IS SUBJECT TO UPDATING, REVISION AND AMENDMENT. THIS PRESENTATION MAY NOT BE REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS.

Information and opinions contained in this Presentation are provided as at the date of the Presentation, are subject to change without notice and do not purport to contain all information that may be required to evaluate the Issuer. The information in this presentation is in draft form and has not been independently verified. The information in this Presentation does not constitute and may not be relied upon in any manner as legal, tax, investment, accounting, regulatory or other advice whatsoever. You should seek independent and professional advice and conduct an independent investigation and analysis of the information in this Presentation, as well as all public information on the Issuer and any shares, securities or financial instruments of the Issuer (the "Securities"). This Presentation contains forward-looking statements (*i.e.* any statements other than statements regarding historical facts or present facts or circumstances) that reflect the Issuer's management's current views with respect to future events and performance of the Issuer. Forward-looking statements are subject to changing circumstances and should, although the Issuer believes they are reasonable, not be relied upon to materialize or prove to be correct. Actual results or outcome could differ materially from those set out in the forward-looking statements. Certain forward-looking statements may be indicated by the context in which they are made or with words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or similar expressions, or their negative. Certain market and competitive position data contained in this Presentation has been obtained from published and non-published industry publications or reports conducted by third parties. The Issuer has not verified and cannot give any assurances as to the accuracy of such information and the accuracy and completeness of such information is not guaranteed. Certain statements in this Presentation are based on the internal analyses of the Issuer, which may involve assumptions and estimates based on the knowledge and experience of its management. Such observations are not reviewed or verified by any external sources.

Neither the Issuer, nor any of their respective partners, directors, officers, employees, advisers, affiliates, representatives or agents undertake or is under any duty or obligation to update or revise this Presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information or otherwise inform you should any information in this Presentation prove inaccurate, incomplete or, with regards to forward-looking statements, not materialize and disclaim any obligation to do so. None of the foregoing persons accept any responsibility whatsoever for the contents of this Presentation and no representation or warranty, expressed or implied, is made by any such person in relation to the contents of this Presentation, and no reliance should be placed on fairness, accuracy or completeness of the information and opinions contained in this Presentation. The foregoing persons expressly disclaim, to the maximum extent permitted by law, any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in connection with the accuracy or completeness of the information or for any of the opinions contained herein (including forward-looking information, information based on publications or reports by third parties and information based on internal analyses of the Issuer), or any other written or oral information made available in connection with this Presentation, or for any errors, omissions or misstatements contained in this Presentation or such other information. None of the foregoing persons shall have any liability whatsoever (in negligence or otherwise) for any direct, indirect or consequential loss, damages, costs or prejudices whatsoever arising from the use of this Presentation or its contents or otherwise arising in connection with this Presentation.

By attending a meeting where this Presentation is made, by otherwise accessing the Presentation or by signing an agreement to underwrite the Securities you warrant, represent, undertake and acknowledge that: (i) you have read and agreed to comply with the foregoing limitations and restrictions, and (ii) you are able to receive this Presentation without contravention of any applicable legal and regulatory restrictions and you understand the sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

# Company Overview



## Novel Technology

- We are based in Stevenage Bioscience Catalyst (SBC) and developing medicines that **prevent debilitating side-effects** associated with cancer chemo / radiotherapies such as oral mucositis, dermatitis and alopecia so to enhance the clinical outcomes of the anticancer therapeutics
- Our **platform** utilises existing proven vasoconstrictor molecules in novel formulations for a faster protection only to normal mucosa/skin/hair, low-risk development approach, offer attractive partnership potentials for oncology therapeutics
- Compelling pre-clinical data and **positive early clinical results** indicate **35% reduction in severity of radiodermatitis** and **up to 49% reduction in radiation-induced oral mucositis**, support moving pipeline programs into future clinical trials;
- Our experienced **leadership members** work in drug development, clinical trial management, regulatory affairs, pharmaceutical distribution and manufacturing
- We are actively seeking partnerships to support **global multi-centre Phase 2-3 trials and market access**



## Proven Science




## Large Market Opportunity

Backed by:



# The Problem

Cancer chemotherapy and  
radiotherapy side-effects



## The Problem

# Patients undergoing cancer treatment suffer from debilitating side effects

These include elements such as skin damage and hair loss, causing missed treatments, treatment cessation and potentially reduced cancer control, presenting a large unmet medical need and impact on healthcare system costs.




### Radiotherapy Induced Oral Mucositis (RIOM)

**80%** **\$17k**

Of head and neck cancer patients experience oral mucositis

Average healthcare costs /patient



### Radiodermatitis (RD)

**50%** **up to 87%**

Of all cancer patients experience radiodermatitis

Of breast cancer patients experience radiodermatitis



### Chemo-Induced Alopecia (CIA)

**33%** **38%**

Of cancer patients experience CIA on average

Of post-menopausal breast cancer patients reported permanent CIA

## The Market

**There are very limited options for preventative treatment available on the market**

Condition	Approved preventative drugs	Approved preventative devices
 <b>Radiotherapy-induced Oral Mucositis (RIOM)</b>	<p><b>Palifermin (Kepivance)</b> approved only for blood cancers receiving high dose chemotherapy and radiotherapy prior to bone marrow transplantation</p> <p><b>Caphosol (OTC)</b> Mouth wash required to be taken 4x per day with very limited efficacy in real world setting</p>	<p><b>Low level laser therapy (LLLT)</b> Stimulates wound healing and reduces inflammation, material staff time required for administration</p>
 <b>Radiodermatitis</b>	<p><b>No approved preventative drugs</b></p>	<p><b>StrataXRT (and others)</b> OTC medical film to promote moisture and healing, no RCT evidence and lack of broad uptake</p>
 <b>Chemo-induced Alopecia (CIA)</b>	<p><b>No approved preventative drugs</b></p>	<p><b>Cold Caps</b> FDA approved Medical Device. Patient cost approx. £3,500 per course. Limited uptake due to pain. Concerns over metastasis stimulation (Dignitana AB, Paxman Coolers, Penguin Cold Caps, Arctic Cold Caps, Wishcaps and Warrior Caps)</p>

# Our Technology

A preventative, topical solution



## What We Do

# We developed novel medicines to prevent and alleviate the debilitating side-effects of cancer therapies



**Muc1  
(NG11-2)**

**Treats:**

Radiotherapy-induced Oral  
Mucositis (**RIOM**)

**Application:**

Oral topical mouth rinse solution  
once usage



**Derm1  
(NG12-1)**

**Treats:**

Radiodermatitis  
(**RD**)

**Application:**

Dermal topical sprayable solution  
with spray applicator



**Derm2  
(NG13-2)**

**Treats:**


Chemotherapy-induced Alopecia  
(**CIA**)

**Application:**


Scalp topical balm solution  
with comb applicator

# Mechanism of Action

## Prophylactic vasoconstriction to reduce/eliminate the causal origin of inflammation



Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008 Jan;52(1):61-77, viii. doi: 10.1016/j.cden.2007.10.002. PMID: 18154865; PMCID: PMC2266835.




# Mechanism of Action


## Transient Topical Vasoconstriction with pharmaceutical protection to normal tissue only

### 1) Prevent ROS production and its damage to normal tissue

- a. By inducing vasoconstriction in normal tissue, minimise stem cell exposure to cytotoxic drugs, and reduce radiation-related Reactive Oxygen Species (ROS) surrounding the normal basal stem cells




- b. Lower blood supply reduces the production of ROS in normal tissue during radiotherapy, minimising ROS-related DNA damage in stem cells, and reduces inflammation mediated by cytokines and chemokines



### 2) Prevent normal stem cells progressing to apoptosis


- a. Vasoconstriction in normal skin/mucosa leads to a hypoxic environment, causing dividing basal cells to switch through their cell cycle and enter G<sub>0</sub> "sleeping mode", protecting vulnerable proliferating mucosal basal stem cells from radiation/chemo-damage.



- b. Accelerated healing when undamaged basal cells re-enter into the divisional cycle post treatment


### 3) No vasoconstriction and no cell cycle impact in cancerous tissue, enhancing chemo-exposure and radiotherapy effects

- a. Cancerous vasculature lacks intact smooth muscle in the blood vessel walls, so it cannot vasoconstrict, even when exposed to an α1 agonist, maximising the effect of chemo/radiotherapy




## Our Products

**Data shows that our novel products alleviate the debilitating side-effects of cancer therapies**




### NG11-2 in Radiation-Induced Oral Mucositis (RIOM)

100% prevention of RIOM on hamster oral mucosa with positive dose dependence



### NG12-1 in Radiodermatitis (RD)

100% prevention of RD on rat skin with positive dose dependence



### NG13 in Chemo-induced Alopecia (CIA)

100% protection against CIA in mice with linear dose-response

# Our Products

Results from data are very promising

# Therapeutic products at clinical stages



### Mouth Rinse

Oral Topical



### Spray Solution

Dermal Topical



### Solution (Balm)

Scalp Topical

#### Products & Indications

**Muc1 (NG11-2)**  
Prevent Radiation-Induced  
Oral Mucositis (RIOM)

**Derm1 (NG12-1)**  
Prevent Radiation  
dermatitis (RD)

**Derm2 (NG13-2)**  
Prevent Chemo-Induced  
Alopecia (CIA)

#### Target patient group (addressable populations in 2030)

Head & neck cancer  
(US 58K / EU137K /  
Global 880K)

Radiotherapy patients  
(US 1M / EU 1.5M / Global  
8M)

Chemotherapy patients  
(US 600K / EU 940K /  
Global 5M)

#### Development Status


Phase-1b trial (UK) **successful**,  
preparing Phase 2/3 trial with  
commercial scale manufacturing

IIT Phase-2a **successful**, launching  
'Named Patient Supply Programme',  
**Out-licensing for Phase 3** and  
commercialisation in progress


Pre-clinical POC **completed**  
**Preparing Phase2/3 trial** with  
scalable manufacturing

# Products positioned to optimise cancer patient care

## 😊 Cancer care pathway with VasoDynamics' products



## 😦 Cancer care pathway without VasoDynamics' products



## Our products

# Benefit to patients, reduce burden to healthcare providers & healthcare systems

1

**Improved cancer therapy tolerance**

Leads to:

- ✓ Greater patient compliance

2

**Better patient quality of life**

Leads to:

- ✓ Greater patient acceptability

3

**Fewer hospitalisations**

Leads to:

- ✓ A reduction in healthcare systems burden
- ✓ Healthcare supplier cost savings

4

**Fewer dose reduction/delays**

Leads to:

- ✓ Improved duration of therapy
- ✓ Payor/pricing leverage

**Potential to **improve** key clinical outcomes**

## Our products

# Positive Clinical Trial Results To-Date

### Derm1 (NG12-1)

Radiodermatitis

Phase 1/1b in USA  
Completed  
with no safety finding

Phase 2a (IIT)  
N=9, Breast Pts NG12-1  
Thirty daily treatments, dermal topically applied minutes before radiotherapy, were well tolerated and representing a mean **35% reductions** in radiodermatitis severity with **statistical significance (P = 0.022)**.

<https://pubmed.ncbi.nlm.nih.gov/29273054/>

### Derm2 (NG13-2)

Chemotherapy-induced Alopecia

Phase 1  
(shared data with Derm1 and Muc2);  
Phase-1b study in USA  
N=3, H&N Pts, NG13-1  
Thirty daily treatments, scalp topically applied,  
no serious adverse events, and no evidence for increased drug substance plasma levels secondary to transdermal absorption.  
*Internal Report PC5*

Phase 2-3 Pivotal  
MHRA SA confirmed UK-AUS Pivotal trial protocol and MA approach,  
Trial preparation ongoing

### Muc1 (NG11-2)

Radiation-induced Oral Mucositis

Phase-1b study in UK  
N=15, H&N Pts, NG11-2  
30-35 daily mouth rinse, before radiotherapy,

were **well tolerated** and representing preliminary **40-49% reduction** of the incidence of severe RIOM comparing to the control groups reported in the literature.

<https://www.isrctn.com/ISRCTN87831050>

Phase 2-3 Pivotal  
MHRA, MEB confirmed global trial protocol,  
EMA-FDA PSA ongoing

## Our Products – IP and FTO

# Strong intellectual property protection and full FTO

## Patents Matrix

- Exclusive license of existing global patent from Wisconsin University (WARF) to enable global **Freedom-To-Operate fully**
- In-house new patent on indication, formulation and manufacturing global PCT filed in Oct 2022, entering EU, US, Japan, China, Israel etc 9 countries & regions in 2024, **expires in 2042**
- New clinical trial design and patient group selection patent global PCT filed in Oct 2023


## Market and Data Protection

- UK-EU-US authorities may issue up to **10 years** of market exclusivity and **8 years** of data exclusivity to supply market protection to drugs like Muc1, Derm1 and Derm2
- Potential paediatric extension (505A/PUMA)

# Development Pipelines




# Development pipeline and focus



# Blockbuster potential & rapid growth

Blockbuster status of total sales expected by 2031-2032



Individual product sales on left-hand scale, total sales on right-hand scale

Preclinical programmes and non-pharmaceutical programmes

# Pharmaceutical pipelines

Programme	Indication	Screening	Formulation	<i>In vitro</i>	<i>In vivo</i>
<b>Muc1-P</b>	Paediatric oral mucositis				
<b>Muc2</b>	Oesophagus mucositis				

# Non-pharmaceutical products

Product	Function	Prototype	Dossier prep	Registration	Distribution
<b>ANOXY Serum</b>	Daily dermal protection				
<b>ANOXY Balm</b>	Daily scalp protection				

# Experienced UK management team and Board



Management
Board

**Ningfeng Fiona Li**  
MD PhD MSc  
**Co-Founder, CEO, CSO**  
Medical doctor specialised in radiation oncology, PhD scientist in cancer biology, serial entrepreneur in oncology drug discovery and development.



Management
Board

**Hilary Birrell**  
BSc  
**Head of Clinical Operations**  
Clinical Research Professional with 35 years of experience in Clinical Trial Operations across multiple areas of healthcare.



Management
Board

**Wills Hughes-Wilson**  
**Non-Executive Director**  
Mereo BioPharma executive, has 20+ years' experience in biopharma leadership, specializing in strategic market pathways and commercial delivery.



Management
Board

**Peter McGowan**  
ACCA  
**CFO**  
Accountant with over 30 years of experience in both public and private companies, spanning multiple sectors, with a specialism in life sciences and tech.



Management
Board

**Austin Smith**  
MD, DPhm  
**Deputy Medical Officer**  
Highly experienced medical oncologist with proven track record in managing and supporting clinical trials and medical affairs.



Management
Board

**Emma Palmer Foster**  
MA, MBA  
**BD & IR Manager**  
Proven track record on corporate and financial strategy, investor relations and financial communications. Ex-senior equity analyst in life science banking industry.



Management
Board

**Gary Bower**  
BSc  
**Head of Clinical Development**  
Chemistry by training, experienced in biotech project management and clinical development management.



Management
Board

**Joseph Irwin**  
MSc, MRSB, FTOPRA, FRSM, FRSS FZS  
**Regulatory Advisor**  
Highly experienced regulatory professional, leading on European Regulatory Agency interactions and International Regulatory Affairs.



Management
Board

**Dawn Adkin**  
PhD BPharm  
**CMC Advisor**  
Proven senior manager with 8+ years at AstraZeneca, skilled pharmaceutical CMC consultant specialised in small molecule pharmaceuticals.



*VasoDynamics*

**Innovate for a better  
life living with cancer**

**Contact**

**Ningfeng Fiona Li, CEO**

[fiona.li@vasodynamics.co.uk](mailto:fiona.li@vasodynamics.co.uk)

